Health News Releases

  • Today April 21
November 08, 2023 16:55
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening
Crown Bioscience (https://www.crownbio.com/), a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidX
International Postdoctoral Scholars in Cancer Research, Class of 2023. Back Row: Dongqi Xie, Ph.D. (
November 08, 2023 16:50
Mary Kay Ash Foundation℠ Celebrates Five Years Shaping the Future of Cancer Research in Partnership With UT Southwestern Medical Center
The Mary Kay Ash Foundation (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmarykayashfoundation.org%2F&esheet=53709537&newsitemid=20231107256704&lan=en-US&anchor=The+Mary+Kay+Ash+F
November 08, 2023 10:48
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational o
HistoSonics Edison Histotripsy System (Photo: Business Wire)
November 07, 2023 14:05
HistoSonics Notches Significant Reimbursement Wins
HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System and novel sonic beam therapy, announced today that the Centers of Medicare & Medicaid Services (CMS)
November 05, 2023 10:20
Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial
Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The results showed a significant reduction of albuminuria, a
November 05, 2023 09:50
Trailblazing the Future of Healthy Aging Science: Timeline® Hosts the First Global Urolithin A Summit With a Full-day Virtual Experience
On November 7th, the first global Urolithin A Scientific Summit, brought to the world stage by Timeline, is set to present paradigm-shifting research in the field of longevity. Led by experts in the s
T cells helping immune system to fight cancer cells in response to immunotherapies (Photo: Business
November 03, 2023 09:10
GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies
GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80 percent accuracy[1], based on a pan-cancer cohort, according to findings to be presented a
November 02, 2023 09:40
Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma
Resolian (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.resolian.com%2F&esheet=53720760&newsitemid=20231101490232&lan=en-US&anchor=Resolian&index=1&md5=1df79e5a4d8ec439af5c7de1
October 31, 2023 16:25
ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced it will present preclinical data demonstrating novel and proprietary lipid nanoparticle (LNP)-base
Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare
October 30, 2023 17:37
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldw
October 29, 2023 12:30
United States International Trade Commission Issues Exclusion Order for Infringing Apple Watches, Finding that Apple Violated U.S. Trade Laws
Masimo (https://www.masimo.com/)(NASDAQ: MASI) today announced that the United States International Trade Commission (USITC) has recommended a limited exclusion order for infringing Apple Watches with
October 27, 2023 17:27
Boehringer Ingelheim’s SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Foundation. The Prix Galien USA Award was presented last
October 27, 2023 16:50
GC Aesthetics and Bimini Health Tech Form Strategic Partnership to Advance Breast Reconstruction Solutions Globally
GC Aesthetics®, a long-established brand in breast aesthetics, and Bimini Health Tech (“Bimini”), a pioneer in healthcare solutions, are pleased to announce their groundbreaking Joint Venture partners
October 27, 2023 11:40
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Manag
October 26, 2023 14:25
Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis Patients
Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults
October 26, 2023 14:10
EnginZyme Produces Key mRNA Vaccine Ingredient Using Biocatalysis
EnginZyme AB, a deep-tech company whose cell-free biomanufacturing technology uses the power of enzymes to create sustainable products and processes for a variety of industries, announced that it had
October 24, 2023 16:25
Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2
Iksuda Therapeutics (Iksuda), the developer of class leading antibody drug conjugates (ADCs) with enhanced tumour specificity, today announces that the first patient has completed a first cycle of the
October 24, 2023 09:00
ImmuneOncia Announces Positive Phase 1a Results of CD47 Monoclonal Antibody IMC-002 in Solid Tumors at ESMO 2023
ImmuneOncia (http://www.immuneoncia.com/immun/) (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at th
Bringing together, all stakeholders involved in research on physical, chemical, and biological realm
October 20, 2023 16:50
Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.
Harshavardhan Sai Sadineni and Srived Meda of Kasturba Medical College, Manipal, India, won the XVIII Fujio Cup Quiz (FCQ) on Stem cells and Regenerative medicine (RM) in the NCRM NICHE 2023; Sri Rama
October 20, 2023 15:30
Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases
Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) (https://pci.com/drug-development-manufacturing-se
The new UVDI-GO UV LED Surface Sanitizer inactivates C. difficile spores in only 20 seconds from 4"
October 20, 2023 10:20
New UVDI-GO™ UV LED Surface Sanitizer Inactivates High-Risk Microorganisms in 20 Seconds or Less
UltraViolet Devices, Inc. (UVDI), a leading manufacturer of advanced UV-C disinfection technology, announced today that the new UVDI-GO™ UV LED Surface Sanitizer is now available for use in healthcare
October 20, 2023 09:30
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its ap
October 19, 2023 10:55
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com&esheet=53633640&newsitemid=20231018884948&lan=en-US&anchor=Takeda&index=1&md5=4152f7bcff17087740131abae020a992)
October 18, 2023 15:30
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (
October 18, 2023 14:54
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53624835&newsitemid=20231017233540&lan=en-US&anchor=TSE%3A4502%2FNYSE%
25 per page50 per page75 per page100 per page